• Home
  •  / GenMark Diagnostics

GenMark Diagnostics

  • Revenue$171.6 MFY, 2020
  • Market Capitalization$1.8 B2021-04-26

OverviewSuggest Edit

GenMark Diagnostics is a provider of automated, multiplex molecular diagnostic testing systems. The Company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.  It offers four Food and Drug Administration -cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. GenMark also offers a Hepatitis C genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only. 

TypePublic
Founded2010
HQCarlsbad, CA, USMap
Websitegenmarkdx.com
Employee Ratings3.2
Overall CultureBMore
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)437(-8%)
Revenue (FY, 2020)$171.6 M(+95%)
Share Price (Apr 2021)$24
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at GenMark Diagnostics

Tanya Monga

Tanya Monga

Chief Executive Officer
Wade Stevenson

Wade Stevenson

Senior Vice President, North America Sales
Tracy Clements

Tracy Clements

Legal Partner
Mirco Woldert

Mirco Woldert

Head of Finance, IT & Facilities
Al Maderazo

Al Maderazo

Vice President, Quality, Regulatory, and Clinical Affairs
Kunal Sur

Kunal Sur

Head of Engineering & Technology
Show more

GenMark Diagnostics Office Locations

GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations
Carlsbad, CA, US (HQ)
5964 La Place Ct
Albany, NY, US
Albany, NY, USA
Atlanta, GA, US
Atlanta, GA, USA
Birmingham, AL, US
Birmingham, AL, USA
Boston, MA, US
Boston, MA, USA
Bristol, TN, US
Bristol, TN, USA
Show all (33)

GenMark Diagnostics Financials and Metrics

GenMark Diagnostics Revenue

Embed Graph
View revenue for all periods
GenMark Diagnostics's revenue was reported to be $171.55 m in FY, 2020
USD

Revenue (FY, 2020)

171.6m

Gross profit (FY, 2020)

67.9m

Gross profit margin (FY, 2020), %

39.6%

Net income (FY, 2020)

(18.6m)

EBIT (FY, 2020)

(11.1m)

Market capitalization (26-Apr-2021)

1.8b

Closing stock price (26-Apr-2021)

24.0

Cash (31-Dec-2020)

40.6m

EV

1.8b
GenMark Diagnostics's current market capitalization is $1.8 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Revenue

5.0m20.5m27.4m30.6m39.4m49.3m52.5m88.0m171.6m

Revenue growth, %

12%29%25%

Cost of goods sold

6.2m11.6m15.9m13.1m15.3m19.7m32.5m59.4m103.6m

Gross profit

(1.2m)8.8m11.5m17.5m24.1m29.6m20.0m28.6m67.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

901.0k1.3m2.2m3.6m5.3m11.1m5.2m4.6m7.9m6.6m6.3m10.1m7.6m8.5m11.1m12.5m10.8m12.5b12.4m11.6m14.9m15.8m18.4m20.9m38.7m40.1m

Cost of goods sold

1.3m1.8m1.7m2.2m3.0m5.0m3.2m4.1m3.7m3.2m2.7m4.0m3.3m3.4m4.4m4.7m4.4m6.4b7.5m7.4m10.5m10.2m11.8m13.9m22.6m24.2m

Gross profit

(393.0k)(469.0k)472.0k1.4m2.2m6.1m2.0m499.0k4.2m3.4m3.6m6.1m4.4m5.1m6.7m7.8m6.5m6.2b4.9m4.2m4.4m5.6m6.6m7.1m16.2m15.9m

Gross profit Margin, %

(44%)(36%)22%40%42%55%39%11%53%51%57%61%57%60%60%62%60%49%40%36%30%36%36%34%42%40%
show all
Annual
USDY, 2009Y, 2010Y, 2011FY, 2011Y, 2012FY, 2012Y, 2013FY, 2013Y, 2014FY, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Cash

16.5m51.3m25.3m25.3m51.3m51.3m35.7m35.7m36.9m36.9m35.4m35.4m16.0m26.8m44.4m40.6m

Accounts Receivable

1.1m3.2m2.9m4.9m6.8m10.7m16.8m20.8m

Prepaid Expenses

322.0k226.0k552.0k575.0k591.0k1.8m1.9m2.7m

Inventories

2.2m2.0m2.1m2.1m2.1m2.1m3.1m3.1m3.1m10.9m11.3m21.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

43.5m31.0m23.8m64.2m53.4m32.0m18.8m63.3m27.9m26.8m25.7m36.9m32.1m34.2m27.9m29.6m19.3m13.2m88.4m27.2m28.9m25.0m23.7m24.3m26.3m82.4m57.8m

Accounts Receivable

640.0k724.0k1.1m1.3m1.2m4.4m4.4m2.4m2.6m2.1m2.7m4.4m4.3m5.4m5.4m5.1m7.3m7.8m7.1m9.9m6.8m10.4m25.7m17.9m16.2m

Prepaid Expenses

495.0k428.0k135.0k192.0k183.0k382.0k772.0k682.0k627.0k1.1m1.2m770.0k874.0k623.0k1.3m1.2m1.3m2.0m1.9m1.9m2.1m2.1m1.8m1.8m2.8m

Inventories

1.2m2.0m2.1m1.9m2.1m3.2m3.4m2.0m1.8m1.2m1.5m2.1m2.0m2.7m2.4m2.6m4.2m9.0m7.1m7.1m8.8m11.3m9.9m12.6m9.9m14.9m19.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(24.0m)(22.1m)(33.6m)(38.3m)(42.2m)(50.6m)(61.8m)(47.3m)(18.6m)

Depreciation and Amortization

1.3m1.2m2.5m2.7m3.4m3.9m5.3m7.3m7.1m

Inventories

(1.7m)(880.0k)(1.3m)(229.0k)(1.3m)(3.4m)(10.5m)(6.5m)(12.5m)

Accounts Payable

378.0k728.0k1.3m85.0k(757.0k)4.1m2.6m1.5m5.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(12.2m)(18.5m)(5.6m)(11.2m)(17.4m)(4.2m)(12.2m)(23.0m)(8.8m)(20.0m)(29.7m)(9.9m)(33.4m)(13.0m)(25.9m)(37.9m)(25.4m)(37.1m)(7.0m)

Depreciation and Amortization

622.0k948.0k264.0k576.0k918.0k498.0k1.0m1.9m574.0k1.2m1.9m797.0k2.7m900.0k1.8m2.7m2.5m3.8m3.5m5.3m3.6m5.4m1.8m3.5m5.4m

Inventories

(275.0k)(1.4m)757.0k1.1m(402.0k)(1.5m)(1.8m)(216.0k)169.0k608.0k209.0k(366.0k)(980.0k)501.0k306.0k1.0m(2.6m)(4.8m)(353.0k)(3.8m)(1.4m)(5.5m)920.0k(5.0m)(10.2m)

Accounts Payable

1.4m510.0k(112.0k)369.0k907.0k129.0k(310.0k)570.0k(449.0k)(501.0k)(318.0k)(775.0k)(358.0k)617.0k1.3m916.0k(3.1m)(1.5m)(1.9m)(3.4m)(1.1m)345.0k(1.6m)3.6m7.4m
show all
Show all financial metrics

GenMark Diagnostics Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Issued

130120100

Patents Pending

253530

GenMark Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

Learn more about our premium products
SecurityScorecard logo

GenMark Diagnostics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

GenMark Diagnostics Online and Social Media Presence

GenMark Diagnostics's Trends

Embed Graph

GenMark Diagnostics Company Culture

  • Overall Culture

    B

    74/100

  • CEO Rating

    C-

    64/100

  • Compensation

    B

    74/100

Learn more on Comparably

GenMark Diagnostics News and Updates

March 20, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMK

NEW YORK, March 19, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City,...
March 15, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GenMark Diagnostics, Inc. Buyout

WILMINGTON, Del., March 15, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GenMark Diagnostics, Inc. (“GenMark”) (NASDAQ GM: GNMK) regarding possible breaches of fiduciary duties and other violations of law related to GenMark’s agreement to be acquired by Roche Hol…
March 15, 2021

Stocks making the biggest moves in the premarket: GenMark Diagnostics, AMC Entertainment, Eli Lilly & more

Names on the move ahead of the open.
March 15, 2021

Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

             Basel, 15 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics (NASDAQ: GNMK) today announced that they have entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of US$ 24.05 per share in an all-cash transaction. This corresponds to…
February 16, 2021

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health…
November 05, 2020

GenMark Diagnostics to Participate in the Canaccord Virtual MedTech & Diagnostics Forum

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Virtual MedTec…
Show more

GenMark Diagnostics Blogs

November 29, 2021

Detection of Omicron variant on the ePlex® RP2 Panel

August 17, 2021

Protected: IDWeek 2021

There is no excerpt because this is a protected post.
June 03, 2021

World Microbe Forum 2021

April 28, 2021

Welcome Wade Stevenson, SVP North America Sales

February 25, 2021

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results Content Import Thu, 02/25/2021 - 16:08 GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results February 25, 2021 This release is a backfill from a News Wire Ear…
February 25, 2021

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

CARLSBAD, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020 .
Show more

 GenMark Diagnostics Frequently Asked Questions

  • When was GenMark Diagnostics founded?

    GenMark Diagnostics was founded in 2010.

  • Who are GenMark Diagnostics key executives?

    GenMark Diagnostics's key executives are Tanya Monga, Wade Stevenson and Tracy Clements.

  • How many employees does GenMark Diagnostics have?

    GenMark Diagnostics has 437 employees.

  • What is GenMark Diagnostics revenue?

    Latest GenMark Diagnostics annual revenue is $171.6 m.

  • What is GenMark Diagnostics revenue per employee?

    Latest GenMark Diagnostics revenue per employee is $392.6 k.

  • Who are GenMark Diagnostics competitors?

    Competitors of GenMark Diagnostics include Nelson Labs, IsoPlexis and Cue.

  • Where is GenMark Diagnostics headquarters?

    GenMark Diagnostics headquarters is located at 5964 La Place Ct, Carlsbad.

  • Where are GenMark Diagnostics offices?

    GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations.

  • How many offices does GenMark Diagnostics have?

    GenMark Diagnostics has 33 offices.